BRCA2 and ovarian carcinoma: We nextevaluated the ability of RTx-303 to potentiate olaparib in ID8 Trp53–/–;Brca2–/– mouse cellswhich are used as a model for ovarian cancer. ID8 Trp53–/–;Brca2–/– cells were sensitive to olaparib (2 μM IC50), potentiatedthe activity of olaparib as expected (Figure A; 0.12 μM IC50).